In this image from video provided by the University of Maryland School of Medicine, Lawrence Faucette, a pig heart transplant patient, works with a physical therapist at the school's hospital in Baltimore, Md., on Wednesday, Oct. 18, 2023. (Tom Jemski/University of Maryland School of Medicine via AP)
Lawrence Faucette was dying from heart failure and ineligible for a traditional heart transplant because of other health problems when doctors at the University of Maryland School of Medicine offered the highly experimental surgery.
In the first glimpse of Faucette provided since the Sept. 20 transplant, hospital video shows physical therapist Chris Wells urging him to smile while pushing through a pedaling exercise to regain his strength.
“That’s going to be tough but I’ll work it out,” Faucette, 58, replied, breathing heavily but giving a smile.
The Maryland team last year performed the world’s first transplant of a heart from a genetically altered pig into another dying man. David Bennett survived just two months before that heart failed, for reasons that aren’t completely clear although signs of a pig virus later were found inside the organ. Lessons from that first experiment led to changes before this second try, including better virus testing.
Attempts at animal-to-human organ transplants — called xenotransplants — have failed for decades, as people’s immune systems immediately destroyed the foreign tissue. Now scientists are trying again using pigs genetically modified to make their organs more humanlike.
In Friday’s hospital video, Faucette’s doctors said the pig heart has shown no sign of rejection.
“His heart is doing everything on its own,” said Dr. Muhammad Mohiuddin, the Maryland team’s cardiac xenotransplantation chief.
A hospital spokeswoman said Faucette, of Frederick, Maryland, has been able to stand and physical therapists are helping him gain strength needed to attempt walking.
Many scientists hope xenotransplants one day could compensate for the huge shortage of human organ donations. More than 100,000 people are on the nation’s list for a transplant, most awaiting kidneys, and thousands will die waiting.
A handful of scientific teams have tested pig kidneys and hearts in monkeys and in donated human bodies, hoping to learn enough for the Food and Drug Administration to allow formal xenotransplant studies.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Energy Vault, the company developing sustainable, grid-scale energy storage solutions, is now trading on the New York Stock Exchange following the completion of its business combination with Novus Capital Corporation II. Energy Vault develops sustainable, grid-scale energy storage solutions designed to advance the transition to a carbon free, resilient power grid. Robert Piconi, co-founder and CEO of Energy Vault, joins Cheddar News' Closing Bell to disucss.
In an effort to fight climate change several corporations have vowed to work to fight climate change by 2030. They say the goal is to reduce carbon emissions by 40% or even close to 100%. However, according to a new study, many of these companies are not actually practicing what they preach. Tom Egger, senior lecturer at Emeritus at the University of Wisconsin, joins Cheddar News to discuss more.
At-home medical labs company Getlabs raised $20 million in a Series A round, led by Emerson Collective and the Minderoo Foundation. Getlabs aims to be the boots-on-the-ground partner to telehealth. The company says more than 70% of medical decisions still require collecting diagnostic tests in person, and that it fills that void by delivering health care directly to their patients' homes. Founder & CEO of Getlabs Kyle Michelson joined Cheddar News' Closing Bell to discuss.
Kalle Marsal, Chief Operating Officer at PetDx, joins Cheddar Innovates to discuss how next-generation sequencing technology is being used to detect cancer in pets early.
On this episode of Cheddar Innovates: WALDO CEO breaks down why now is a good time to make eyecare a priority, and how they are democratizing access to eyecare for all; COO at PetDx explains how next-generation sequencing technology is being used to detect cancer in pets early; Cheddar gets a look at Curiosity Stream's 'Inside The Mind of a Con Artist.'
Shares of Canadian cannabis giant Canopy Growth surged after the company reported Q3 earnings Wednesday morning, with shares up more than 15 percent at the close of the day's trading session. Despite net revenue declining year-over-year, Canopy beat analyst expectations and has ramped up efforts to develop a "THC ecosystem' in the U.S. Canopy Growth's CEO, David Klein, joined Cheddar News' Closing Bell to discuss the report. He noted that its brands Storz & Bickel vaporizers and BioSteel beverages showed record growth.
The Central Park Conservancy announced last month it has partnered with the Yale School of the Environment and the New York City-based Natural Areas Conservancy to study the on-the-ground impacts of climate change on urban parks. Salmaan Khan, Director of Research and Special Projects at the Central Park Conservancy joins Cheddar Climate to explain what factors put this initiative into motion and what data his team will be looking to uncover.
Energy Impact Partners is a VC firm committed to helping the world move toward a more sustainable future. The tech-focused fund aims to reach $350 million for its Deep Decarbonization Frontier Fund,' which aims to support early-stage companies working on innovative solutions. Energy Impact Partners' Managing Director Andy Lubershane joined Cheddar Climate to discuss.
Mukul Bakhshi, Chief of Strategy and Government Affairs for CGFNS International, joins Cheddar News to discuss strained U.S. hospitals seeking foreign nurses.
The Democratic governors of New Jersey, Connecticut, Delaware, and Oregon say they will lift mask requirements for schools in the coming weeks, reflecting a nationwide shift away from restrictions. Cheddar News speaks with internist Dr. Vivek Cherian whether it's safe to relax the regulation.
